|
Description of Business (Details)
|
Sep. 30, 2012
|
|---|---|
| Description of Business [Abstract] | |
| Number classes of preclinical antibodies | 3 |
| Number of product candidates on rights to develop and commercialize | 1 |
| Number of product candidates on option to develop and commercialize | 2 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of classes of preclinical antibodies for the treatment of diabetes. No definition available.
|
| X | ||||||||||
|
- Definition
The number of product candidates the entity has option to develop and commercialize. No definition available.
|
| X | ||||||||||
|
- Definition
The number of product candidates the entity has right to develop and commercialize. No definition available.
|